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RESEARCH ARTICLE
Serum S-100B levels in children with Subacute Sclerosing Panencephalitis
Subakut Sklerozan Panensefalit’li çocuklarda serum S-100B düzeyleri
İbrahim Hocanlı1, Mustafa Çalık2, Alpay Çakmak1, Hakim Çelik3, Abdürrahim Kocyiğit3, Akın İşcan2
ÖZET
Amaç: S-100B santral sinir sisteminde yaygın olarak bu-
lunan, kan beyin bariyeri yıkımında ve nöronal hasarda 
periferik belirteç olarak kullanılan bir proteindir. Bu çalış-
manın amacı, Subakut sklerozan panensefalitli hastalar-
da S-100B düzeylerini araştırmaktır.
Gereç ve yöntem: Çalışmada, SSPE’ li 40 hasta ile 40 
sağlıklı kontrol grubu alındı. Serum S-100B protein kon-
santrasyonları elektrokemiluminesan immunoassay (EC-
LIA) yöntemi ile üretici standartlarına göre ölçüldü.
Bulgular: Ortalama S-100B seviyeleri SSPE’li hasta gru-
bunda 0.095 ± 0.017 μg/L, kontrol grubunda ise 0.097 ± 
0.019 μg/L bulundu. Aralarında istatistiksel olarak anlamlı 
farklılık bulunmadı (p>0.05). Hasta grubu beyin atrofisinin 
varlığına göre iki altgruba ayrıldı. S-100B seviyeleri be-
yin atrofisi olan grupta 0.096±0.018 μg/L, atrofisi olmayan 
grupta ise 0.094±0.014 μg/L idi. Bu farklılık istatistiksel 
olarak anlamlı değildi (p>0.05). 
Sonuç: Bizim sonuçlarımız, S-100B’nin SSPE’ de nöro-
nal hasarda güvenilir bir belirteç olmadığını göstermek-
tedir.
Anahtar kelimeler: Subakut sklerozan panensefalit, S-
100B seviyesi, serum biomarker 
ABSTRACT
Objectives:  S-100B  a  protein  prevalent  in  the  central 
nervous system is a peripheral biomarker for blood-brain 
barrier disruption and neuronal damage. The objective of 
the study was to investigate the S-100B levels in patients 
with subacute sclerosing panencephalitis.
Materials and methods: A  group  of  40  patients  with 
SSPE  and  40  healthy  controls  were  recruited.  Serum 
S-100B protein concentrations were measured using a 
commercially  available  electrochemiluminescence  im-
munoassay (ECLIA) kit, as supplied and according to the 
manufacturer’s standards.
Results: Median S-100B levels were 0.095 ± 0.017 μg/L 
in patients with SSPE and 0.097±0.019 μg/L in the con-
trol group. This difference was not statistically significant 
(p>0.05). The patient group was further subdivided into 
two subgroups according to the presence or absence of 
brain atrophy. The S-100B levels were 0.096 ± 0.018 μg/L 
in the subgroup with atrophy and 0.094±0.014 μg/L in the 
subgroup without atrophy. This difference was also not 
statistically significant (p>0.05).
Conclusions: Our results suggest that serum S-100B is 
not a reliable marker for neuronal damage in SSPE. J Clin 
Exp Invest 2012; 3 (3): 331-334
Key words:  Subacute  sclerosing  panencephalitis,  S-
100B level, serum biomarker 
INTRODUCTION
Subacute  sclerosing  panencephalitis  (SSPE) is  a 
progressive  neurologic  disorder  of  childhood  and 
early  adolescence  that  develops  as  a  sequel  to 
early childhood measles infection. The incidence of 
SSPE has declined substantially since the develop-
ment of the measles vaccination. However, it still 
remains a problem in developing countries. The di-
agnosis of the disease is based on clinical and neu-
roimaging findings, electroencephalography (EEG) 
results, and the titer of measles antibodies in the 
cerebrospinal fluid (CSF) and serum. There is cur-
rently no objective laboratory finding monitoring the 
course of the disease. No peripheral biomarker is 
currently in use apart from imaging methods.1
S-100B is a calcium-binding protein primarily 
present in nervous tissue. Elevated S-100B levels 
are detected as a marker of injury to the astrocytes 
even after mild head injury 2, in children with septic 
encephalopathy  and in newborns after prolonged Hocanlı et al. Serum s100B levels in SSPE 332
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labor 3, and they are also associated with a number 
of other diseases, e.g. migraine, epilepsy, cardio-
myopathy,  cancer  and  inflammatory  and  autoim-
mune diseases.4,5
In this study, we measured the levels of S-100B 
protein which is a biochemical marker of neuronal 
damage in SSPE patients and control subjects.
MATERIALS AND METHODS
Study population
This prospective study was conducted at the Pe-
diatric Neurology Department of Harran University 
School of Medicine, Sanliurfa, in Turkey. The study 
was  conducted  from  October  2004  to  December 
2010. The case group consisted of 40 children who 
were admitted to the hospital following SSPE. The 
control group was consisted of 40 healthy children. 
SSPE was diagnosed by the Dyken Criteria.6 Neu-
rological disability index (NDI) developed by Dyken 
et al. was used in scoring the clinical neurological 
abnormalities  of  the  cases.  The  method  recom-
mended by Jabbour 7 was used in clinical staging. 
The study was conducted according to the princi-
ples approved by Harran University Hospital ethics 
committee. Informed consent was obtained from the 
parents or guardians. Patients were excluded from 
the study if findings showed septic encephalopathy, 
hypoxia, and recent neurosurgery operation.
Data collection
The clinical data collected on all patients included 
the following: 1) demographics (age and gender), 
mean age of having measles, and measles vaccina-
tion status; 2) Serum measles IgG levels and CSF 
measles IgG levels 3) EEG and brain magnetic res-
onance imaging (MRI). A brain MRI was performed 
using a Siemens 1.5 Tesla system device (Signa; 
GE Medical Systems, Milwaukee, WI). An EEG was 
performed using a Nihon-Kohden device that took 
digital recordings from 16 surface electrodes placed 
according to the international 10-20 system.
Sample collection
Serum samples were collected from patients upon 
admission. Standard hematological and biochemi-
cal analyses of peripheral blood were also docu-
mented. Blood samples were obtained from the 40 
healthy age- and sex-matched control children. The 
serum samples were centrifuged, and the superna-
tants were frozen at -70°C until assayed.
Analyzing S-100B levels
Serum  S-100B  protein  concentrations  were  mea-
sured  using  a  commercially  available  electroche-
miluminescence immunoassay (ECLIA) kit, Roche 
Diagnostics (Germany) as supplied and according 
to the manufacturer’s standards. The sensitivity of 
the kit was 0.005-0.105 µg/L.
Statistical Analysis
All statistical analyses were performed using SPSS 
for Windows version 11.5 (SPSS, Chicago, IL, USA). 
Distribution of the samples in the groups was ana-
lyzed with one sample of Kolmogorov-Smirnov test. 
The data were expressed as arithmetic means and 
standard deviations. When the two groups are com-
pared; the variables that showed normal distribu-
tion were evaluated using the t-test and the S-100B 
variable that did not show a normal distribution was 
evaluated via Mann-Whitney U test. Whereas, the 
relationship between the qualifier variables was ex-
amined using Chi-square test. P< 0.05 value was 
accepted to be statistically significant.
RESULTS
The study group consisted of 24 males and 16 fe-
males. The mean age of diagnosis of SSPE was 8.2 
± 2.3 (age range 4-13 years). A history of measles 
was present in 33 patients (82.5%). In seven pa-
tients, no information regarding measles could be 
obtained. The  mean  age  of  having  measles  was 
19 ±15.4 months. A measles vaccination had been 
administered to 16 (40%) patients. The history for 
measles vaccination was unclear in 24 out of 40 
patients. The mean duration of the latent period be-
tween having measles and SSPE was 6.3±2.4 (2.7-
11.5 years).
The  serum  S-100B  levels  were  0.095±0.017 
μg/L  in  the  group  of  patients  with  SSPE  and 
0.097±0.019 μg/L in the control group. No statisti-
cally  significant  difference  in  S-100B  levels  was 
found between the SSPE group and control group 
(P=0.692) (Table 1). No statistically significant cor-
relations were determined between the levels of S-
100B and age of diagnosis, age of having measles, 
NDI, and duration of the latent period (P>0.05).
Brain MRI analysis revealed intensity changes 
in  the  cortico-subcortical,  cortico-subcortical  plus 
corpus  callosal,  and  cortico-subcortical  plus  peri-
ventricular regions in 36 (90%), 15 (37.5%) and 14 
(35%) of the subjects, respectively. Atrophy charac-
terized by enlargement of cortical sulci was found in 
12 subjects out of 40, in addition to intensity chang-Hocanlı et al. Serum s100B levels in SSPE 333
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es. The group of patients with SSPE was divided 
into two different subgroups according to the pres-
ence of brain atrophy.
Table 1. Age, sex, body mass index and S-100B level in 
patient and control groups
Patients 
(n=40)
Controls 
(n=40) P-value
Age (years) 11.30±1.80* 10.91±1.80* 0.338
Sex (B/G) 24/16 22/18 0.651
BMI (kg/m²) 17.65±2.86 17.4±1.79 0.659
S-100B (µg/L) 0.095± 0.017* 0.097±0.019* 0.692
* Given as the mean ± SD, BMI: Body mass index
The S-100B levels were 0.096±0.018 μg/L in 
the subgroup of cases with SSPE and atrophy and 
0.094±0.014  μg/L  in  the  subgroup  of  cases  with 
SSPE lacking atrophy. The NDI scores of subjects 
with atrophy (determined using brain MRI analysis) 
were significantly higher compared to subjects with-
out atrophy (P<0.001). No statistically significant dif-
ference in S-100B levels was determined between 
the subgroup with atrophy and the subgroup without 
atrophy (P=0.299) (Table 2).
Table 2: Comparison of S-100B levels and neurological 
disability index scores in 40 patients with and without at-
rophy determined using brain MRI
Atrophy present
(n=28)
No atrophy
(n=12) P-value
NDI score (points) 55.2±13.0 33.8±1.0 0.001
S-100B (µg/L) 0.096±0.018* 0.094± 0.014* 0.299
* Given as the mean ± SD, NDI: Neurological disability 
index
DISCUSSION
Subacute sclerosing panencephalitis is a devastat-
ing disease, beginning as minor disturbances in be-
havior in a previously healthy child. Subsequently, 
myoclonic  attacks  develop  and  become  increas-
ingly more frequent. Dementia follows, and within 
months or a few years, the child is comatose and 
void of higher brain functions. Clinical findings and 
brain imaging methods have had great importance 
in the monitoring of patients diagnosed with SSPE. 
Even  though  imaging  methods  make  significant 
contributions to the display of brain damage in pa-
tients, the severity of the sickness does not always 
coincide with the brain MRI findings.8,9
Studies  on  neurobiochemical  and  immuno-
logic markers correlated with brain damage have 
gained  interest  in  recent  years.4,5  Some  proteins 
are thought of as peripheral biochemical markers 
of neuronal damage and glial injury or activation. 
According to this opinion, an available peripheral 
evaluation would represent a milestone for the di-
agnosis  and  follow-up  of  central  nervous  system 
diseases.10
S-100B  is  the  most  analyzed  brain-derived 
peripheric biochemical marker in brain damage. S-
100B is a low molecular weight protein mainly de-
rived from the brain (intrathecal fraction = ~99%; 
CSF/serum ratio: 18:1). In healthy subjects, natural 
autoantibodies to S-100B of IgG class are present 
in serum. However, the exact source of S-100B in 
the  blood  is  unknown. At  normal  concentrations, 
S-100B  is  able  to  protect  hippocampal  neurons 
against  glutamate  toxicity.11  It  has  been  demon-
strated  that  S-100B  suppresses  copper-induced 
oxidative stress. At higher levels (micromolar), S-
100B  causes  exacerbation  of  neuroinflammation, 
oxidative stress and neuronal apoptosis. Increases 
in S-100B levels may reflect the extent of glial dam-
age or astrocytic reactions to neural injury (reactive 
astrogliosis).12
It has been found that in animal models, CSF 
increases rapidly due to traumatic or focal ischemic 
events and that in hypoxic ischaemic encephalopa-
thy, this increase occurs prior to radiologic and clini-
cal findings.13,14 It has been hypothesized that high 
serum  S-100B  levels  are  an  indicator  of  neuron 
breakdown or more likely an indicator of the regen-
erative activity that takes place in response to an 
unknown degenerative process.5
Recent studies indicate that oxidative damage 
causing  an  increase  in  reactive  oxygen  products 
plays an important role in the pathogenesis of neu-
rodegenerative diseases such as SSPE.15,16 In this 
regard, it is thought that the inflammatory reactions 
responsible for the pathogenesis of SSPE might be 
related to the biological functions of S-100B. Fur-
thermore, the S-100B protein levels may show the 
neuronal damage that develops during the inflam-
matory process.17
Yuksel et al. 18 suggest that there is no differ-
ence in the CSF S-100B and Tau protein levels of 
newly diagnosed SSPE patients in comparison with 
control groups. Our findings are consistent with this 
study.  No  statistically  significant  relationship  was 
determined in terms of S-100B levels of SSPE pa-
tients and control groups in our study, which aimed 
to examine the effect of neuron damage on system-Hocanlı et al. Serum s100B levels in SSPE 334
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ic circulation in SSPE via S-100B measurements in 
peripheric blood.
It  is  known  that  S-100B  concentrations  in-
crease  in  acute  schizophrenia  and  decrease  in 
chronic schizophreni.19 In a study by Chaves et al. 
20 on Alzheimer patients, serum S-100B levels were 
lower compared to healthy controls, whereas the 
serum  S-100B  levels  showed  no  correlation  with 
morphological  changes,  such  as  cortical  atrophy 
determined by brain MRI. Even though it was stated 
in previous studies that the S-100B levels were high 
for acute encephalitis patients, the fact that it was 
determined to be normal in our study may be due to 
the fact that SSPE is a subacute viral encephalitis.21
In conclusion, even though the existence of at-
rophy in brain MRI findings is an indicator of neuron 
loss, no statistically significant difference was de-
termined in our study between the S-100B levels of 
patients with atrophy and those with no atrophy de-
velopment. This finding indicates that serum S-100B 
levels cannot be taken as a criterion for demonstrat-
ing the functional losses along with the reflection of 
atrophy. Even though the results obtained in this 
study indicate that serum S-100B levels cannot be 
used as a peripheral marker for the evaluation of 
brain damage in SSPE, the study does not conclu-
sively demonstrate that S-100B does not contribute 
to the pathogenic process in SSPE. This topic can 
be clarified in future studies.
REFERENCES
1. Garg RK. Subacute sclerosing panencephalitis. J Neu-
rol 2008;14(12):1439-52.
2. Geyer C, Ulrich A, Grafe G, stach B, Till H. Diagnostic 
value of S 100B and neuron- specific enolase in mild 
pediatric traumatic brain injury. J neurosurg Pediatr 
2009;4(2):339-44.
3. Schulpis KH, Margeli A, Akalestos A, et al. Effects of 
mode of delivery on maternal-neonatal plasma anti-
oxidant status and on protein S-100B serum concen-
trations. Scand J Clin Lab Invest 2006;66(6):733-42.
4. Gazzolo D, Abella R, Marinoni E, et al. New markers 
of neonatal neurology. J Maternal-Fetal Neonat Med 
2009;12(1): 1-5.
5. Rothermundt M, Peters M, Prehn JH, Arolt V. S100B in 
brain damage and neurodegenaration. Microsc Res 
Tech 2003;60(5):614-32.
6. Dyken PR. Subacute sclerosing panencephalitis. Neu-
rol Clin 1985;3(2):179-95.
7. Jabbour JT, Garcia JH, Lemmi H, Ragland J, Duenas 
DA, Sever JL. Subacute sclerosing pan encephalitis. 
JAMA 1969;207(12):2248-54.
8. Oztürk A, Gürses C, Baykan B, Gökyigit A, Eraksoy 
M. Subacute sclerosing panencephalitis: Clinical and 
magnetic  resonance  imaging  evaluation  of  36  pa-
tients. J Child Neurol 2002;17(1):25-9.
9. Aydin K, Okur O, Tatli B, Sarwar SG, Ozturk C, Dilber 
C. Reduced gray matter volume in the frontotemporal 
cortex of patients with early subacute sclerosing pan-
encephalitis. AJNR Am J Neuroradiol 2009;30(2):271-
5. 
10.  Lins  H,  Wallesch  CW,  Wunderlich  MT.  Sequential 
analyses  of  neurobiochemical  markers  of  cerebral 
damage in cerebrospinal fluid and serum in CNS in-
fections. Acta Neurol Scand 2005;112(2):303-08.
11. Ahlemeyer B, Beier H, Semkova I, Schaper C, Kriegl-
stein J. S-100beta protects cultured neurons against 
glutamate- and staurosporine-induced damage and is 
involved in the antiapoptotic action of the 5 HT(1A)-
receptor agonist, Bay x 3702. Brain Res 2000;858(1): 
121-8.
12. Van Eldik LJ, Wainwright MS. The Janus face of glial 
derived S100B: beneficial and detrimental functions 
in the brain. Restor Neurol Neurosci 2003;21(3-4):97-
108.
13. Giussani DA, Thakor AS, Frulio R, Gazzolo D. Acute 
hypoxia  increases  S100beta  protein  in  association 
with blood flow redistribution away from peripheral cir-
culations in fetal sheep. Pediatr Res 2005;58(2):179-
84. 
14. Oses JP, Leke R, Portela LV, et al. Biochemical brain 
markers and purinergic parameters in rat CSF after 
seizure induced by pentylenetetrazol. Brain Res Bull 
2004; 64(2): 237-42.
15. Simonian NA, Coyle JT. Oxidative Stres in Neuro-
degenerative Diseases. Ann Rev Pharmacol Toxicol 
1996;36(1):83-106.
16. Michael T, Lin, M. Mitochondrial dysfunction and oxi-
dative stress in neurodegenerative diseases. Nature 
2006;443(3):787-95.
17. Li SW, Barger L, Liu RE, Mrak MST. S100b induction 
of the proinflammatory cytokine interleukin-6 in neu-
rons. J Neurochem 2000;74(1):143-50.
18. Yuksel D, Yilmaz D, Uyar NY, Senbil N, Gurer Y, Anlar 
B. Tau proteins in the cerebrospinal fluid of patients 
with subacute sclerosing panencephalitis. Brain Dev 
2010;32(3): 467-71. 
19. Wiesmann M, Wandinger KP, Missler U, Eckhoff D, 
Rothermundt M, Arolt V, et al. Elevated plasma levels 
of S-100b protein in schizophrenic patients. Biol Psy-
chiatry 1999;45:1508-11.
20. Chaves ML, Camozzato AL, Ferreira ED, et al. Se-
rum levels of S100B and NSE proteins in Alzheimer’s 
disease patients. J Neuroinflammation 2010; 7(1):1-6.
21. Gazzolo D, Grutzfeld Dariusz, et al. Increased S100B 
in cerebrospinal fluid of infants with bacterial menin-
gitis: Relationship to brain damage and routine cere-
brospinal fluid findings. Clin Chem 2004;50(8):941-4. 